Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma
Low-grade HER2-positive breast carcinomas constitute mostly low-stage, luminal-type, and apparently low-risk tumors, warranting investigation into whether therapy de-escalation could achieve favorable outcomes with less toxicity in this population.
Authors
- Eric Quentin Konnick (ORCID: https://orcid.org/0000-0001-5904-1788)
- Hannah M. Linden (ORCID: https://orcid.org/0000-0001-5048-2819)
- A. Menicucci
- William R. Gwin (ORCID: https://orcid.org/0000-0001-6314-0965)
- William Audeh (ORCID: https://orcid.org/0000-0002-7790-7466)
- Lavanya Samraj
- Natasha Hunter
- Haley Corbin (ORCID: https://orcid.org/0000-0002-0079-4459)
- Lisa Han (ORCID: https://orcid.org/0000-0002-1541-8771)
- Shaveta Vinayak (ORCID: https://orcid.org/0000-0001-9197-7316)
Institutions
- University of Pittsburgh (US)
- University of Washington (US)
- Lakeridge Health (CA)
- Agendia (Netherlands) (NL)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1093/ajcp/aqaf010
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00